Why Novocure Stock Fell 24.4% This Week
Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment.
Stay updated with breaking news from Novocure Ttfields. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment.
Novocure shares plunged after the provider of cancer-fighting treatments reported a Phase 3 trial of its Tumor Treating Fields (TTFields) therapy for ovarian cancer patients failed to meet its goal.
The company disappointed investors with its latest clinical trial update.
Most Wall Street analysts think this stock will skyrocket. They could be right.
Novocure’s electrical field-producing medical device, in combination with standard drug therapies, improved overall survival in a pivotal study that enrolled patients with advanced non-small cell lung cancer. The medtech company now plans to seek regulatory approvals.